

## **BenevolentAI publishes 2022 Annual Report**

**London, UK, 21 March 2023:** BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces that the Annual Report and Accounts for the year ended 31 December 2022 (the "2022 Annual Report") has been published.

The 2022 Annual Report is available on the Company's website at [www.benevolent.com/investors/reports-and-presentations/](http://www.benevolent.com/investors/reports-and-presentations/), and at the Company's registered office.

### **Enquiries:**

#### **Investors:**

Fleur Wood – VP Investor Relations

fleur.wood@benevolent.ai

[investors@benevolent.ai](mailto:investors@benevolent.ai)

T: +44(0) 203 781 9360

### **About BenevolentAI**

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers the Company's in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.